[go: up one dir, main page]

WO1999003885B1 - Antitumoral composition based on immunogenic polypeptide with modified cell location - Google Patents

Antitumoral composition based on immunogenic polypeptide with modified cell location

Info

Publication number
WO1999003885B1
WO1999003885B1 PCT/FR1998/001576 FR9801576W WO9903885B1 WO 1999003885 B1 WO1999003885 B1 WO 1999003885B1 FR 9801576 W FR9801576 W FR 9801576W WO 9903885 B1 WO9903885 B1 WO 9903885B1
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic polypeptide
papillomavirus
polypeptide
seq
composition according
Prior art date
Application number
PCT/FR1998/001576
Other languages
French (fr)
Other versions
WO1999003885A1 (en
Filing date
Publication date
Priority claimed from FR9709152A external-priority patent/FR2766091A1/en
Priority to DK98939708T priority Critical patent/DK0989999T3/en
Priority to AU88127/98A priority patent/AU749054B2/en
Priority to JP2000503107A priority patent/JP4489288B2/en
Priority to EP98939708A priority patent/EP0989999B1/en
Priority to CA2296797A priority patent/CA2296797C/en
Application filed filed Critical
Priority to DE69826661T priority patent/DE69826661T2/en
Priority to US09/462,993 priority patent/US6884786B1/en
Priority to AT98939708T priority patent/ATE277947T1/en
Publication of WO1999003885A1 publication Critical patent/WO1999003885A1/en
Publication of WO1999003885B1 publication Critical patent/WO1999003885B1/en
Priority to US11/072,288 priority patent/US7332478B2/en

Links

Abstract

The invention concerns an antitumoral composition comprising as therapeutic agent one or several immunogenic polypeptides, of which at least one is modified so as to have a cell location different from its native location. The invention also concerns a composition based on a recombinant vector expressing said immunogenic polypeptide. It further concerns a recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from a precocious and/or tardive region of a papillomavirus having a modified location and a viral particle comprising said vector. Finally it concerns the therapeutic use of said composition, said recombinant vector and said viral particle.

Claims

REVENDICATIONS MODIFIEES[reçues par le Bureau international le 21 janvier 1999 (21.01.99); revendication 1 modifiée; revendications 11-39 modifiées et renumérotées 11-38; autres revendications inchangées (8 pages)] AMENDED CLAIMS [received by the International Bureau on 21 January 1999 (21.01.99); amended claim 1; claims 11-39 modified and renumbered 11-38; other claims unchanged (8 pages)]
1. Composition antitumorale comprenant à titre d'agent thérapeutique ou prophylactique un ou plusieurs polypcptidc(s) immunogènc(s), caractérisée en ce que l'un au moins desdits polypeptides est originaire d'une région précoce et/ou tardive d'un papillomavirus et, notamment d'un papillomavirus humain (HPV) de type 16, 18, 31, 33 ou 45, et est modifié de manière à présenter une localisation différente de sa localisation native.An antitumor composition comprising, as therapeutic or prophylactic agent, one or more polypeptide (s) immunogen (s), characterized in that at least one of said polypeptides originates from an early and / or late region of a papillomavirus and, in particular, a human papillomavirus (HPV) type 16, 18, 31, 33 or 45, and is modified so as to have a different location from its native location.
2. Composition antitumorale selon la revendication 1, caractérisée en ce que la modification du polypeptide est obtenue par l'introduction de signaux de localisation appropriés et/ou la délétion ou l'inactivation des signaux de localisation natifs.2. antitumor composition according to claim 1, characterized in that the modification of the polypeptide is obtained by the introduction of appropriate localization signals and / or the deletion or inactivation of the native location signals.
3. Composition antitumorale selon l'une des revendications 1 ou 2, dans laquelle le polypeptide immunogène ayant naturellement une localisation non membranaire, notamment nucléaire, est modifié de manière à présenter une localisation membranaire.3. Antitumor composition according to one of claims 1 or 2, wherein the immunogenic polypeptide naturally having a non-membrane localization, in particular nuclear, is modified so as to have a membrane localization.
4. Composition antitumorale selon la revendication 3, dans laquelle le polypeptide immunogène est modifié par insertion d'une séquence d'ancrage membranaire et, le cas échéant, d'une séquence de sécrétion.Antitumor composition according to claim 3, wherein the immunogenic polypeptide is modified by insertion of a membrane anchoring sequence and, if appropriate, a secretion sequence.
5. Composition selon l'une des revendications 1 à 4, caractérisée en ce que le polypeptide est délété de sa séquence de localisation nucléaire.5. Composition according to one of claims 1 to 4, characterized in that the polypeptide is deleted from its nuclear localization sequence.
6. Composition antitumorale selon l'une des revendications 1 à 5, dans laquelle la séquence de sécrétion et/ou d'ancrage membranaire est sélectionnée parmi le groupe constitué par celle de la glycoprotéine rabique, de la glycoprotéine env du virus HIV et de la protéine F du virus de la rougeole. 6. Antitumor composition according to one of claims 1 to 5, wherein the secretion sequence and / or membrane anchor is selected from the group consisting of that of the rabies glycoprotein, the glycoprotein env of the HIV virus and the F protein from the measles virus.
Composition antitumorale selon l'une des revendications 1, 2 ou 5, dans laquelle le polypeptide immunogène est modifié de manière à présenter une localisation cytoplasmique, notamment par mutation/délétion des signaux de localisation natifs. Antitumor composition according to one of claims 1, 2 or 5, wherein the immunogenic polypeptide is modified so as to have a cytoplasmic localization, in particular by mutation / deletion of native localization signals.
Composition antitumorale selon l'une des revendications 1 , 2 ou 5, dans laquelle le polypeptide immunogène est modifié par insertion, notamment à son extrémité C-terminale d'une séquence permettant une localisation dans un compartiment cellulaire particulier.Antitumor composition according to one of claims 1, 2 or 5, wherein the immunogenic polypeptide is modified by insertion, particularly at its C-terminal end of a sequence for localization in a particular cell compartment.
Composition antitumorale selon la revendication 8, dans laquelle le polypeptide immunogène est modifié par insertion, notamment à son extrémité C-terminale d'une séquence d'endocytose et, en particulier, de la séquence IPNYRNM.Antitumor composition according to claim 8, wherein the immunogenic polypeptide is modified by insertion, in particular at its C-terminal end of an endocytosis sequence and, in particular, the IPNYRNM sequence.
10. Composition antitumorale selon la revendication 8, dans laquelle le polypeptide immunogène est modifié par insertion, notamment à son extrémité C-terminale d'une séquence permettant un ancrage dans la membrane de l'appareil de Golgi.10. anti-tumor composition according to claim 8, wherein the immunogenic polypeptide is modified by insertion, in particular at its C-terminal end of a sequence allowing anchoring in the membrane of the Golgi apparatus.
1 1. Composition antitumorale selon l'une des revendications 1 à 10, dans laquelle le polypeptide immunogène dérive d'un polypeptide de la région précoce d'un papillomavirus et, notamment de E6 ou E7.1. Antitumor composition according to one of claims 1 to 10, wherein the immunogenic polypeptide derives from a polypeptide of the early region of a papillomavirus and, in particular E6 or E7.
12. Composition antitumorale selon la revendication 11, dans laquelle le polypeptide immunogène dérive d'un variant non oncogène dudit polypeptide E6 ou E7 d'un papillomavirus.The anti-tumor composition of claim 11, wherein the immunogenic polypeptide is derived from a non-oncogenic variant of said E6 or E7 polypeptide of a papillomavirus.
13. Composition antitumorale selon l'une des revendications 1 à 10, dans laquelle le polypeptide immunogène dérive du polypeptide Ll ou L2 d'un papillomavirus.Antitumor composition according to one of claims 1 to 10, wherein the immunogenic polypeptide derives from the L1 or L2 polypeptide of a papillomavirus.
14. Composition antitumorale selon l'une des revendications 1 à 13, comprenant au moins un polypeptide immunogène dérivant d'un polypeptide précoce et au moins un polypeptide immunogène dérivant d'un polypeptide tardif d'un papillomavirus. 14. Antitumor composition according to one of claims 1 to 13, comprising at least one immunogenic polypeptide derived from an early polypeptide and at least one immunogenic polypeptide derived from a late polypeptide of a papillomavirus.
15. Composition antitumorale selon l'une des revendications 1 à 14, comprenant :Antitumor composition according to one of claims 1 to 14, comprising:
( 1) un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1 ,(1) an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 1,
(2) un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2,(2) an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 2,
(3) un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1 et un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, (4) un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1, un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus,(3) an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1 and an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 2 (4) an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 1, an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or an immunogenic polypeptide derived from the protein L2 of a papillomavirus,
(5) un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus, ou(5) an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 2, an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or an immunogenic polypeptide derived from the L2 protein a papillomavirus, or
(6) un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1, un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus.(6) an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1, an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 2 , an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or an immunogenic polypeptide derived from the L2 protein of a papillomavirus.
16. Composition antitumorale selon l'une des revendications 1 à 15, comprenant en outre au moins un composé améliorant l'effet antitumoral de ladite composition.16. antitumor composition according to one of claims 1 to 15, further comprising at least one compound improving the antitumor effect of said composition.
17. Composition antitumorale selon la revendication 16, dans laquelle ledit composé est un immunostimulateur. The antitumor composition of claim 16, wherein said compound is an immunostimulator.
18. Composition antitumorale selon la revendication 17, dans laquelle ledit composé immunostimulateur est sélectionné parmi le groupe constitué par l'interleu ine-2, l'interleukinc-7, l'interleukine-12 et les molécules de co-adhésion B7.1 et B7.2.The anti-tumor composition of claim 17, wherein said immunostimulatory compound is selected from the group consisting of interleu-2, interleukin-7, interleukin-12, and B7.1 co-adhesion molecules and B7.2.
19. Composition antitumorale qui comprend à titre d'agent thérapeutique ou prophylactique au moins un vecteur recombinant comprenant les séquences codant pour un ou plusieurs polypeptide(s) immunogène(s), l'un au moins desdits polypeptides étant originaire d'une région précoce et/ou tardive d'un papillomavirus et, notamment d'un papillomavirus humain (HPV) de type 16, 18, 31, 33 ou 45, et étant modifié de manière à présenter une localisation différente de sa localisation native et, éventuellement, pour un composé améliorant l'effet antitumoral de ladite composition.19. Antitumor composition which comprises as therapeutic or prophylactic agent at least one recombinant vector comprising the sequences coding for one or more immunogenic polypeptide (s), at least one of said polypeptides originating in an early region. and / or late of a papillomavirus and, in particular of a human papillomavirus (HPV) of type 16, 18, 31, 33 or 45, and being modified so as to have a location different from its native location and, possibly, to a compound improving the antitumor effect of said composition.
20. Composition antitumorale selon la revendication 19, dans laquelle lesdits polypeptides immunogènes et améliorant l'effet antitumoral ont les caractéristiques telles que définies à l'une quelconque des revendications 1 à 18.20. An antitumor composition according to claim 19, wherein said immunogenic and antitumor effect enhancing polypeptides have the characteristics as defined in any one of claims 1 to 18.
21. Composition antitumorale selon la revendication 19 ou 20, dans laquelle le vecteur recombinant dérive d'un poxvirus et notamment d'un virus de la vaccine, d'un canaripox et d'un fowlpox.21. Anti-tumor composition according to claim 19 or 20, wherein the recombinant vector derives from a poxvirus and in particular from a vaccinia virus, a canaripox and a fowlpox.
22. Composition antitumorale selon la revendication 21, dans laquelle le vecteur recombinant dérive d'un virus de la vaccine sélectionné parmi les souches Copenhague, Wyeth et Ankara modifiée (MVA).22. An antitumor composition according to claim 21, wherein the recombinant vector is derived from a vaccinia virus selected from Copenhagen, Wyeth and Modified Ankara (MVA) strains.
23. Composition antitumorale selon la revendication 22, dans laquelle le vecteur recombinant dérive d'un virus de la vaccine de la souche Copenhague et les séquences codant pour le ou lesdits polypeptides sont insérées au niveau du locus TK et/ou K1L dudit virus de la vaccine.23. Antitumor composition according to claim 22, wherein the recombinant vector is derived from a vaccinia virus of the Copenhagen strain and the sequences coding for the said polypeptide (s) are inserted at the TK locus and / or K1L of said virus of the vaccinated.
24. Composition antitumorale selon la revendication 22, dans laquelle le vecteur recombinant dérive d'un virus de la vaccine de la souche MVA et les séquences codant pour le ou lesdits polypeptides sont insérées au niveau de l'une au moins des zones d'excision I à VI dudit virus de la vaccine et, notamment II et/ou III.24. An antitumor composition according to claim 22, wherein the recombinant vector is derived from a vaccinia virus of the MVA strain and the sequences coding for said polypeptide (s) are inserted at at least one of the excision zones I to VI of said vaccinia virus and, in particular, II and / or III.
25. Composition antitumorale selon l'une des revendications 21 à 24, dans laquelle les séquences codant pour le ou lesdits polypeptides sont placées sous le contrôle d'un promoteur d'un gène d'un virus de la vaccine et, notamment d'un promoteur sélectionné parmi les promoteurs des gènes thymidine kinase (TK), 7,5K, H5R p28, pl l et KlL.25. Antitumor composition according to one of claims 21 to 24, wherein the sequences encoding the polypeptide or polypeptides are placed under the control of a promoter of a gene of a vaccinia virus and, in particular, a promoter selected from the promoters of thymidine kinase (TK) genes, 7.5K, H5R p28, pI and KlL.
26. Composition antitumorale selon l'une des revendications 21 à 25, destinée au traitement ou la prévention d'une infection ou tumeur à papillomavirus, comprenant au moins un vecteur recombinant dérivé d'un virus de la vaccine de la souche Copenhague ou MVA dans lequel sont insérées :26. anti-tumor composition according to one of claims 21 to 25, for the treatment or prevention of an infection or papillomavirus tumor, comprising at least one recombinant vector derived from a vaccinia virus strain Copenhagen or MVA in which are inserted:
(1) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID(1) sequences encoding an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID
NO: 1,NO: 1,
(2) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, (3) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1 et pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2,(2) sequences coding for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 2, (3) sequences coding for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1 and for an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 2,
(4) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID(4) sequences encoding an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID
NO: 1, pour un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou pour un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus,NO: 1, for an immunogenic polypeptide deriving from the L1 protein of a papillomavirus and / or for an immunogenic polypeptide derived from the L2 protein of a papillomavirus,
(5) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID(5) sequences encoding an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID
NO: 2, pour un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou pour un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus, ou (6) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1, pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, pour un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou pour un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus.NO: 2, for an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or for an immunogenic polypeptide derived from the L2 protein of a papillomavirus, or (6) sequences coding for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1, for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 2, for an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or for an immunogenic polypeptide derived from the L2 protein of a papillomavirus.
27. Composition antitumorale selon la revendication 26, comprenant en outre les séquences codant pour un composé immunostimulateur, de préférence, choisi parmi LTL-2 ou B7.1.27. Antitumor composition according to claim 26, further comprising the coding sequences for an immunostimulatory compound, preferably selected from LTL-2 or B7.1.
28. Composition antitumorale selon l'une des revendications 19 à 27, dans laquelle le vecteur recombinant est vivant ou tué.28. Antitumor composition according to one of claims 19 to 27, wherein the recombinant vector is alive or killed.
29. Composition antitumorale selon l'une des revendications 1 à 28, comportant un support acceptable d'un point de vue pharmaceutique permettant son administration par injection à l'homme ou à l'animal.29. antitumor composition according to one of claims 1 to 28, comprising a pharmaceutically acceptable carrier for its administration by injection to humans or animals.
30. Vecteur recombinant comprenant au moins les séquences codant pour un polypeptide immunogène originaire d'une région précoce et/ou tardive d'un papillomavirus, ledit polypeptide ayant les caractéristiques définies aux revendications 1 à 15.30. Recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from an early and / or late region of a papillomavirus, said polypeptide having the characteristics defined in claims 1 to 15.
31. Vecteur recombinant selon la revendication 30, comprenant en outre une ou plusieurs séquences codant pour un polypeptide d'intérêt, notamment un polypeptide immunogène et/ou un polypeptide immunostimulateur. The recombinant vector of claim 30, further comprising one or more sequences encoding a polypeptide of interest, including an immunogenic polypeptide and / or an immunostimulatory polypeptide.
32. Vecteur recombinant selon la revendication 30 ou 31, dérivant d'un vecteur plasmidique ou viral, notamment d'un poxvirus et en particulier d'un virus de la vaccine de la souche Copenhague ou MVA.32. Recombinant vector according to claim 30 or 31, derived from a plasmid or viral vector, in particular a poxvirus and in particular a vaccinia virus of the Copenhagen or MVA strain.
33. Vecteur recombinant selon la revendication 32, dérivant d'un virus de la vaccine de la souche Copenhague ou MVA dans lesquels sont insérées : (1) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1, (2) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2,33. Recombinant vector according to claim 32, derived from a vaccinia virus of Copenhagen strain or MVA in which are inserted: (1) the coding sequences for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1, (2) sequences encoding an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 2,
(3) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1 et pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2,(3) sequences coding for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1 and for an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in FIG. SEQ ID NO: 2,
(4) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1, pour un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou pour un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus,(4) sequences coding for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1, for an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or for a polypeptide immunogen derived from the L2 protein of a papillomavirus,
(5) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, pour un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou pour un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus, ou(5) sequences coding for an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in SEQ ID NO: 2, for an immunogenic polypeptide derived from the L1 protein of a papillomavirus and / or for a polypeptide immunogen derived from the L2 protein of a papillomavirus, or
(6) les séquences codant pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 1, pour un polypeptide immunogène ayant une séquence homologue ou identique à tout ou partie de celle montrée dans la SEQ ID NO: 2, pour un polypeptide immunogène dérivant de la protéine Ll d'un papillomavirus et/ou pour un polypeptide immunogène dérivant de la protéine L2 d'un papillomavirus.(6) sequences coding for an immunogenic polypeptide having a sequence homologous or identical to all or part of that shown in SEQ ID NO: 1, for an immunogenic polypeptide having a sequence homologous to or identical to all or part of that shown in FIG. SEQ ID NO: 2, for an immunogenic polypeptide derived from the LI protein of a papillomavirus and / or for an immunogenic polypeptide derived from the L2 protein of a papillomavirus.
34, Particule virale comprenant un vecteur recombinant selon l'une des revendications 30 à 33.34, virus particle comprising a recombinant vector according to one of claims 30 to 33.
35. Particule virale selon la revendication 34, dans laquelle ledit polypeptide immunogène est ancré dans la structure protéique entourant ladite particule virale.The viral particle of claim 34, wherein said immunogenic polypeptide is anchored in the protein structure surrounding said virus particle.
36. Utilisation d'une composition antitumorale selon l'une des revendications 1 à 29, d'un vecteur recombinant selon l'une des revendications 30 à 33 ou d'une particule virale selon la revendication 34 ou 35, pour la préparation d'un médicament destiné au traitement ou à la prévention d'un cancer ou d'une tumeur.36. Use of an antitumor composition according to one of claims 1 to 29, a recombinant vector according to one of claims 30 to 33 or a viral particle according to claim 34 or 35, for the preparation of a drug for the treatment or prevention of cancer or a tumor.
37. Utilisation selon la revendication 36, pour la préparation d'un médicament destiné au traitement ou à la prévention d'un cancer du col de l'utérus, d'une dysplasie du col de bas grade et d'une infection à papillomavirus.37. Use according to claim 36 for the preparation of a medicament for the treatment or prevention of cervical cancer, low grade cervical dysplasia and papillomavirus infection.
38. Utilisation selon la revendication 36 ou 37, pour la préparation d'un médicament injectable par la voie intramusculaire. 38. Use according to claim 36 or 37 for the preparation of an injectable medicament by the intramuscular route.
PCT/FR1998/001576 1997-07-18 1998-07-17 Antitumoral composition based on immunogenic polypeptide with modified cell location WO1999003885A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT98939708T ATE277947T1 (en) 1997-07-18 1998-07-17 ANTITUMORAL COMPOSITION OF IMMUNOGENIC POLYPETIDS WITH ALTERED CELL LOCALIZATION
AU88127/98A AU749054B2 (en) 1997-07-18 1998-07-17 Antitumoral composition based on immunogenic polypeptide with modified cell location
JP2000503107A JP4489288B2 (en) 1997-07-18 1998-07-17 Anti-tumor compositions based on immune polypeptides with altered localization in cells
EP98939708A EP0989999B1 (en) 1997-07-18 1998-07-17 Antitumoral composition based on immunogenic polypeptide with modified cell location
CA2296797A CA2296797C (en) 1997-07-18 1998-07-17 Antitumoral composition based on immunogenic polypeptide with modified cell location
DK98939708T DK0989999T3 (en) 1998-07-17 1998-07-17 Anti-tumor preparation based on immunogenic polypeptide with modified cell localization
DE69826661T DE69826661T2 (en) 1997-07-18 1998-07-17 ANTITUMORAL COMPOSITION OF IMMUNOGENOUS POLYPETIDES WITH CHANGED CELLOCALIZATION
US09/462,993 US6884786B1 (en) 1997-07-18 1998-07-17 Antitumoral composition based on immunogenic polypeptide with modified cell location
US11/072,288 US7332478B2 (en) 1997-07-18 2005-03-07 Antitumoral composition based on immunogenic polypeptide with modified cell location

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97/09152 1997-07-18
FR9709152A FR2766091A1 (en) 1997-07-18 1997-07-18 ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09462993 A-371-Of-International 1998-07-17
US11/072,288 Continuation US7332478B2 (en) 1997-07-18 2005-03-07 Antitumoral composition based on immunogenic polypeptide with modified cell location

Publications (2)

Publication Number Publication Date
WO1999003885A1 WO1999003885A1 (en) 1999-01-28
WO1999003885B1 true WO1999003885B1 (en) 1999-03-04

Family

ID=9509372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/001576 WO1999003885A1 (en) 1997-07-18 1998-07-17 Antitumoral composition based on immunogenic polypeptide with modified cell location

Country Status (11)

Country Link
US (2) US6884786B1 (en)
EP (1) EP0989999B1 (en)
JP (2) JP4489288B2 (en)
AT (1) ATE277947T1 (en)
AU (1) AU749054B2 (en)
CA (1) CA2296797C (en)
DE (1) DE69826661T2 (en)
ES (1) ES2229528T3 (en)
FR (1) FR2766091A1 (en)
PT (1) PT989999E (en)
WO (1) WO1999003885A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2766091A1 (en) * 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
DE19925199A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy
DE19925235A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US7348014B2 (en) * 2000-04-14 2008-03-25 Transgene, S.A. Poxvirus with targeted infection specificity
AR032712A1 (en) * 2001-02-21 2003-11-19 Solvay Pharm Bv A MESILATE OF PHENYLPIPERAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
AU2003221650A1 (en) * 2002-04-24 2003-11-10 Universite Libre De Bruxelles Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process
DK1944318T3 (en) 2003-07-21 2011-06-14 Transgene Sa Multifunctional cytokines
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AR052743A1 (en) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec PLASMIDIC TRANSFER VECTOR AND RECOMBINANT CANARYPOX VIRUS
US20100061957A1 (en) * 2006-04-21 2010-03-11 Transgene S.A. Hpv-16-based papillomavirus vaccines
EP2013229A2 (en) * 2006-04-21 2009-01-14 Transgene S.A. Hpv-18-based papillomavirus vaccine
CN101063142B (en) * 2006-04-30 2012-08-22 中国医学科学院基础医学研究所 Human papilloma virus 16 type DNA vaccine and gene adjuvant and its application
MX348525B (en) * 2006-06-20 2017-06-16 Transgene Sa Process for producing poxviruses and poxvirus compositions.
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines
US20100003704A1 (en) * 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8420103B2 (en) 2007-01-30 2013-04-16 Transgene S.A. Papillomavirus vaccines
KR101514473B1 (en) 2007-05-15 2015-04-22 트랜스진 에스.에이. Multigene Expression Vector
AU2008250521B2 (en) 2007-05-15 2013-04-18 Transgene S.A. Signaling peptides
EA019836B1 (en) * 2007-11-02 2014-06-30 Те Джонс Хопкинс Юниверсити Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
CA2744294A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
HUE025015T2 (en) 2009-01-20 2016-04-28 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
AU2010227611B2 (en) 2009-03-24 2014-05-29 Transgene Sa Biomarker for monitoring patients
CN102395883B (en) 2009-04-17 2015-12-02 特朗斯吉有限公司 For the biomarker of monitored patient
EP2427763A4 (en) 2009-05-07 2013-08-21 Oncohealth Corp Identification of high grade or cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
RU2011148791A (en) 2009-05-12 2013-06-20 Трансген Са IMMORTALIZED BIRD CELL LINES AND THEIR APPLICATION
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
US20120190100A1 (en) 2009-07-21 2012-07-26 Transgene AS Enzymatic composition for the digestion of chicken embryos
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
WO2011073741A1 (en) 2009-12-18 2011-06-23 Transgene Sa A method and a system for automatically processing multiple measurements of biological quantifiable parameters
US9128094B2 (en) 2010-01-08 2015-09-08 Oncohealth Corp. High throughput cell-based HPV immunoassays for diagnosis and screening of HPV-associated cancers
TWI575070B (en) 2011-07-12 2017-03-21 傳斯堅公司 Hbv polymerase mutants
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2836295B1 (en) 2012-04-06 2019-08-28 Life Technologies Corporation Fluid mixing system with flexible drive line
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
KR20150058152A (en) 2012-07-10 2015-05-28 트랜스진 에스아이 Mycobacterial antigen vaccine
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulations and their use
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CN107206063B (en) 2014-12-01 2021-09-28 特兰斯吉恩股份有限公司 Stable liquid vaccinia virus formulations
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP4029599A1 (en) 2015-12-29 2022-07-20 Life Technologies Corporation Fluid mixing system with laterally displaced flexible drive lines and methods of use
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
TW201825674A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing bispecific engager molecules
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
KR102658198B1 (en) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11969462B2 (en) 2017-06-21 2024-04-30 Transgene Personalized vaccine
EP3740561A1 (en) 2018-01-17 2020-11-25 Life Technologies Corporation Fluid mixing systems including helical mixing assembly with impeller attachment and methods of use
BR112020018117A2 (en) 2018-03-07 2020-12-22 Transgene PSEUDOVARIOLA VIRUS (PCPV), METHODS TO GENERATE PCPV AND TO AMPLIFY PCPV, COMPOSITION, METHOD OF TREATMENT, METHOD TO INHIBIT GROWTH OF TUMOR CELLS, USE OR METHOD OF RESULTING AND UNDERSTOVING ETHIOUS PROVISION
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
CN114555129A (en) 2019-09-20 2022-05-27 特兰斯吉恩股份有限公司 Combinations of poxviruses encoding HPV polypeptides and IL-2 with anti-PD-L1 antibodies
JP7712284B2 (en) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ Compositions for improving poxvirus stability
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
CN119654339A (en) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 Fusion protein comprising surfactant protein-D and TNFSF member
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (en) 1985-06-18 1989-11-03 Transgene Sa INTERFERON U EXPRESSION VECTOR IN MAMMALIAN CELLS, PROCESS FOR IMPLEMENTING SAME AND PRODUCT OBTAINED, AND PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON U
FR2583770B1 (en) 1985-06-21 1988-08-19 Transgene Sa EXPRESSION OF HUMAN IL-2 IN MAMMALIAN CELLS BY A RECOMBINANT POXVIRUS
FR2606029B2 (en) * 1986-04-08 1989-02-03 Transgene Sa VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED
FR2600079B1 (en) * 1986-06-16 1989-10-20 Transgene Sa VIRAL VECTOR AND RECOMBINANT DNA ENCODING PROTEIN F OF THE VIRUS CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING THE PROTEIN, OBTAINED PROTEIN, VACCINE AND ANTIBODIES OBTAINED
FR2643817B1 (en) * 1989-03-06 1993-12-17 Transgene Sa PHARMACEUTICAL COMPOSITION, USEFUL AS A PREVENTIVE OR CURATIVE AGAINST TUMORS INDUCED BY PAPILLOMAVIRUS
FR2617715B1 (en) 1987-07-07 1990-08-31 Transgene Sa VIRAL VECTOR AND RECOMBINANT DNA ENCODING FOR ONE OR MORE SURFACE PROTEINS (HA AND / OR F) OF A MORBILLIVIRUS, INFECTED CELL CULTURE, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
SE9101433D0 (en) * 1991-05-13 1991-05-13 Marianne Hansson RECOMBINANT DNA SEQUENCE AND ITS USE
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ATE356142T1 (en) 1991-07-19 2007-03-15 Univ Queensland VACCINE AGAINST HUMAN PAPILLOMAVIRUS (TYPE 18)
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
WO1994017187A1 (en) * 1993-01-29 1994-08-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services CLONING AND EXPRESSION OF PLASMODIUM FALCIPARUM TRANSMISSION-BLOCKING TARGET ANTIGEN, Pfs230
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
FR2727689A1 (en) 1994-12-01 1996-06-07 Transgene Sa NEW PROCESS FOR THE PREPARATION OF A VIRAL VECTOR
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
WO1996039178A1 (en) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
FR2737222B1 (en) 1995-07-24 1997-10-17 Transgene Sa NEW VIRAL AND LINEAR VECTORS FOR GENE THERAPY
AU724621B2 (en) * 1996-01-29 2000-09-28 Georgetown University Amplification of response from expressed recombinant protein
FR2762615B1 (en) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE AND VECTOR CONTAINING THE SAME
FR2766091A1 (en) * 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
AU9231998A (en) * 1997-09-20 1999-04-12 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells

Similar Documents

Publication Publication Date Title
WO1999003885B1 (en) Antitumoral composition based on immunogenic polypeptide with modified cell location
ES2229528T3 (en) ANTITUMORAL COMPOSITION BASED ON MODIFIED CELLULAR LOCALIZATION IMMUNOGEN POLYPETIDE.
ES2163795T5 (en) PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND INFECTIONS BY PAPILOMAVIRUS.
KR20160106082A (en) Immunity enhancing therapeutic vaccine for hpv and related diseases
CN107922981B (en) Promoters for enhanced expression in poxviruses
JP2016502507A (en) Compositions and methods for cancer treatment
US12180501B2 (en) Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer
ES2380731T3 (en) Vaccines based on the use of VMA
JP7670705B2 (en) Medical Use of Recombinant Modified Vaccinia Virus Ankara (MVA) Adjuvanted with 4-1BBL
US7118754B1 (en) Pharmaceutical composition for treating papillomavirus tumors and infection
CA2308127A1 (en) Agonist and antagonist peptides of carcinoembryonic antigen (cea)
US7314629B2 (en) Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus
WO1998015285A1 (en) Methods and compositions for inducing a protective immune response to cancers
WO1998015285A9 (en) Methods and compositions for inducing a protective immune response to cancers
Thomas et al. P03. 02 A mutated prostatic acid phosphatase (PAP) peptide-based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice
JP2001519644A (en) Method of inhibiting cell-mediated killing of target cells
HK1149709B (en) Use of mva to treat prostate cancer
HK1149709A1 (en) Use of mva to treat prostate cancer
AU8723701A (en) Pharmaceutical composition for treating papollomavirus tumour and infection